Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital

The predictive value of ERG protein expression for development of castration-resistant prostate cancer in hormone-naïve advanced prostate cancer treated with primary androgen deprivation therapy

Research output: Contribution to journalJournal articlepeer-review


  1. Prediction of individual genetic risk to prostate cancer using a polygenic score

    Research output: Contribution to journalJournal articlepeer-review

  2. Perinatal exposure to mixtures of anti-androgenic chemicals causes proliferative lesions in rat prostate

    Research output: Contribution to journalJournal articlepeer-review

  3. PrognosticValue of PINP,BoneAlkaline Phosphatase, CTX-I, andYKL-40 in Patients With Metastatic Prostate Carcinoma

    Research output: Contribution to journalJournal articlepeer-review

  1. Open vs robot-assisted radical cystectomy (BORARC): a double-blinded, randomised feasibility study

    Research output: Contribution to journalJournal articlepeer-review

  2. Reply by Authors

    Research output: Contribution to journalComment/debatepeer-review

View graph of relations

BACKGROUND: Biomarkers predicting response to primary androgen deprivation therapy (ADT) and risk of castration-resistant prostate cancer (CRPC) is lacking. We aimed to analyse the predictive value of ERG expression for development of CRPC.

METHODS: In total, 194 patients with advanced and/or metastatic prostate cancer (PCa) treated with first-line castration-based ADT were included. ERG protein expression was analysed in diagnostic specimens using immunohistochemistry (anti-ERG, EPR3864). Time to CRPC was compared between ERG subgroups using multiple cause-specific Cox regression stratified on ERG-status. Risk reclassification and time-dependent area under the ROC curves were used to assess the discriminative ability of ERG-status. Time to PSA-nadir, proportion achieving PSA-nadir ≤0.2 ng/ml, and risk of PCa-specific death were secondary endpoints.

RESULTS: Median follow-up was 6.8 years (IQR: 4.9-7.3). In total, 105 patients (54.1%) were ERG-positive and 89 (45.9%) were ERG-negative. No difference in risk of CRPC was observed between ERG subgroups (P = 0.51). Median time to CRPC was 3.9 years (95%CI: 3.2-5.1) and 4.5 years (95%CI: 2.3-not reached) in the ERG-positive and ERG-negative group, respectively. Compared to a model omitting ERG-status, the ERG-stratified model showed comparable AUC values 1 year (77.6% vs. 78.0%, P = 0.82), 2 years (71.7% vs. 71.8%, P = 0.85), 5 years (68.5% vs. 69.9%, P = 0.32), and 8 years (67.9% vs. 71.4%, P = 0.21) from ADT initiation. No differences in secondary endpoints were observed.

CONCLUSIONS: ERG expression was not associated with risk of CRPC suggesting that ERG is not a candidate biomarker for predicting response to primary ADT in patients diagnosed with advanced and/or metastatic PCa.

Original languageEnglish
JournalThe Prostate
Issue number14
Pages (from-to)1499-509
Number of pages11
Publication statusPublished - Oct 2015

ID: 45853679